Review of progressive multifocal leukoencephalopathy and natalizumab

Allen J Aksamit1

  • 1Mayo Clinic College of Medicine, Department of Neurology, Rochester, Minnesota 55905, USA. aksamit@mayo.edu

The Neurologist
|November 24, 2006
PubMed
Abstract

Insights

Progressive multifocal leukoencephalopathy (PML) is a risk for natalizumab users. Early detection of PML or JC virus is challenging, but natalizumab withdrawal may improve survival in multiple sclerosis patients.

Area of Science:

  • Neurology
  • Infectious Diseases
  • Immunology

Background:

  • Progressive multifocal leukoencephalopathy (PML) is a demyelinating infection affecting oligodendrocytes.
  • PML has been observed in patients undergoing natalizumab treatment.
  • Distinguishing PML from multiple sclerosis (MS) using MRI is difficult; JC virus detection in spinal fluid is specific but not always sensitive.

Purpose of the Study:

  • To evaluate the risk of PML in patients treated with natalizumab.
  • To identify potential methods for early detection and management of PML.
  • To inform risk-benefit assessments for natalizumab therapy in MS patients.

Main Methods:

  • Case review of natalizumab-treated patients.
  • Analysis of diagnostic challenges including MRI and JC virus detection.
  • Assessment of treatment outcomes and risk factors.

Main Results:

  • Natalalizumab is a predisposing factor for PML, with an estimated incidence of 1 in 1000.
  • No reliable presymptomatic surveillance methods for PML or JC virus infection exist.
  • Duration of natalizumab treatment may be an independent risk factor.
  • One patient survived after natalizumab withdrawal and potential antiviral therapy, though immune reconstitution disease is a risk.

Conclusions:

  • PML is a significant risk associated with natalizumab use and should be considered.
  • Treatment of MS with natalizumab involves informed, individualized risk assessment.
  • PML deficits are likely permanent, emphasizing the need for careful patient selection and monitoring.

Related Concept Videos

Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
Encephalitis l: Introduction01:19

Encephalitis l: Introduction

Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...